pab potential, page-43

The 4th Cohort is really a very attractive risk proposition

based on what is already known and has been achieved the drug could really push forward regardless of this outcome the big ticket in this outcome though is HOW MUCH BETTER CAN IT BE ?

It has already showed very convincing evidence & stabilised the disease in two patients while showing no serious side-effects and maintaining a great safety profile - the current drugs to treat MM are highly toxic.

You have to remember these patients had also failed on EVERY OTHER available treatment option for MM.

So to summarise the big thing to look for here is the safety data in the next update but even if it is raised somewhat it's probably inline with currently available therapies & we already know the lower dose has had pretty incredible outcome. Doubling the dose in 4th Cohort is really just firstly measuring the safety of the increase but since we have already seen a significant benefit delivered at a lesser amount what will the outcome be here ? Will the larger dose also significantly improve the outcome ?!?!?!

and even if it doesn't we already know the lower dose has market

Why do you think the FDA / EMA granted orphan already ? I highly doubt they would of if they couldn't already see the potential on what is known.